Our spectral cytometry data show that they are distinct from the recently defined CD14+ DC3 population, and that they are present in the circulation of healthy donors, SARS-CoV-2-infected patients, as well as patients with five different types of cancer. This evidence concerns the gene CD14 and cancer.